• Lactobacillus gasseri Modulates Colitis via NR1I3–E-cadherin

  2026-05-07

  This study uncovers how Lactobacillus gasseri ATCC33323 alleviates DSS-induced colitis in mice by preserving the intestinal mucosal barrier through NR1I3-mediated upregulation of E-cadherin. The mechanistic findings advance our understanding of probiotic action in inflammatory bowel disease and offer translational insights for future therapeutic strategies.

• Recombinant Human Oncostatin M: Cytokine Crossroads in Diffe

  2026-05-06

  Explore the advanced roles of Recombinant Human Oncostatin M in orchestrating cellular differentiation and X-chromosome inactivation. This article integrates new mechanistic insights and practical assay guidance, providing a unique perspective not covered by standard protocol or workflow guides.

• CH 223191: Precision AhR Antagonism for Toxicology & Regener

  2026-05-06

  CH 223191 stands out as a potent aryl hydrocarbon receptor antagonist for researchers aiming to dissect AhR signaling in environmental toxicology and regenerative medicine. This article unpacks validated experimental workflows, troubleshooting insights, and translational applications—bridging the latest mechanistic findings with actionable bench protocols.

• Tigecycline: Glycylcycline Antibiotic for Multidrug-Resistan

  2026-05-05

  Tigecycline from APExBIO offers robust activity against multidrug-resistant bacteria, enabling advanced experimental workflows in resistance research. This article details stepwise protocols, troubleshooting strategies, and the translational significance of recent findings in carbapenem-resistant Enterobacter cloacae for optimizing antimicrobial assays.

• Sisomicin vs. Tobramycin: In Vitro Activity Against Clinical

  2026-05-05

  The referenced study systematically compared the in vitro activity of the aminoglycoside antibiotic sisomicin to gentamicin and tobramycin across a broad panel of clinical Gram-negative and Gram-positive isolates. The findings highlight nuanced differences in efficacy and resistance patterns, informing both antibiotic selection and resistance research strategies.

• IWP-2: Wnt Production Inhibitor for Cancer & Pathway Assays

  2026-05-04

  IWP-2, a potent Wnt production inhibitor from APExBIO, empowers researchers to dissect the Wnt/β-catenin pathway with high specificity and reproducibility. This article delivers practical protocols, troubleshooting tips, and translational insights for leveraging IWP-2 in advanced cancer research and functional genomics.

• D-Lin-MC3-DMA: Ionizable Cationic Liposome for RNA Therapeut

  2026-05-04

  D-Lin-MC3-DMA is a benchmark ionizable cationic liposome lipid, enabling efficient siRNA and mRNA delivery via lipid nanoparticles. Its potency for hepatic gene silencing and endosomal escape is well-documented, with orders-of-magnitude increased efficacy over earlier lipids. This article details mechanistic insight, evidence, and integration protocols for RNA delivery.

• Genistein in Action: Protocols and Troubleshooting for Cance

  2026-05-03

  Harnessing the selective tyrosine kinase inhibition of Genistein empowers researchers to dissect oncogenic signaling and cytoskeleton-driven autophagy with precision. This guide delivers practical protocols, troubleshooting insights, and strategic advantages for maximizing Genistein’s impact in cancer biology workflows.

• Dicloxacillin Efficacy Against S. aureus: Intra- and Extrace

  2026-05-02

  This article analyzes the comprehensive evaluation of dicloxacillin's intra- and extracellular activities against Staphylococcus aureus in both in vitro macrophage and in vivo mouse peritonitis models. The findings highlight the importance of pharmacokinetic/pharmacodynamic (PK/PD) indices—especially fTMIC—in predicting antibiotic efficacy, and offer a framework for optimizing antibacterial testing protocols in persistent staphylococcal infection research.

• Structural Basis of TRPM3 Regulation by Neurosteroids and Dr

  2026-05-01

  This study elucidates the molecular mechanisms by which neurosteroids and anticonvulsants modulate the TRPM3 ion channel, a key player in pain perception and neurodevelopmental disorders. High-resolution cryo-EM structures reveal ligand binding sites and inform targeted therapeutic strategies.

• Estradiol Modulates ER Stress to Restore CD4+ T Cell Functio

  2026-05-01

  This study reveals that 17β-estradiol (E2) normalizes splenic CD4+ T lymphocyte function after hemorrhagic shock by attenuating endoplasmic reticulum (ER) stress via estrogen receptor-α and GPR30 pathways. It further demonstrates that the N-glycosylation inhibitor tunicamycin acts as a robust ER stress inducer, providing a critical mechanistic control for dissecting the role of ER stress in immune dysfunction.

• GLT-1 Upregulation Mitigates TBI via CB1-CREB Pathway Inhibi

  2026-04-30

  This study demonstrates that upregulating GLT-1 expression in astrocytes protects against neuronal apoptosis and cognitive dysfunction after traumatic brain injury (TBI) by inhibiting the CB1-CREB signaling pathway. The findings clarify a mechanistic link between endocannabinoid signaling, glutamate regulation, and neuroprotection, informing experimental approaches for memory impairment research.

• Trifluoperazine 2HCl: Precision Dopamine D2 Receptor Inhibit

  2026-04-30

  Experience unparalleled control in dopamine receptor signaling and macrophage-based research with Trifluoperazine 2HCl. This guide reveals step-by-step workflow enhancements, advanced use-cases, and troubleshooting strategies, empowering high-sensitivity assays in neuropharmacology and immunology.

• Oridonin Suppresses Inflammation in Esophageal Cancer via TL

  2026-04-29

  This study demonstrates that oridonin significantly attenuates inflammation and tumor progression in a mouse model of esophageal cancer by inhibiting the TLR4/NF-κB/NLRP3 inflammasome pathway. The findings clarify mechanisms at the intersection of chronic inflammation and esophageal carcinogenesis, with practical implications for preclinical anti-inflammatory research.

• AM 281: CB1 Cannabinoid Receptor Antagonist in TBI Research

  2026-04-29

  AM 281, a potent and selective CB1 cannabinoid receptor antagonist, empowers researchers to dissect neuroprotective mechanisms in memory impairment and traumatic brain injury models. Its nanomolar affinity, workflow-validated protocols, and APExBIO's trusted supply chain make AM 281 the preferred tool for precision modulation of the cannabinoid receptor signaling pathway in neuropharmacology.

14543 records 1/970 page Next 12345 下5页 Last page